| Company Name: |
Biorbyt Ltd. |
| Tel: |
+44 (0)1223 859 353 |
| Email: |
info@biorbyt.com |
|
| | 4A7C-301-Nurr1 Agonist Basic information |
| | 4A7C-301-Nurr1 Agonist Chemical Properties |
| solubility | DMF: 20 mg/ml
DMSO: 20 mg/ml
Ethanol: 30 mg/ml |
| | 4A7C-301-Nurr1 Agonist Usage And Synthesis |
| Description | 4A7C-301-Nurr1 agonist is an agonist of nuclear receptor-related 1 (Nurr1).1 It binds to the Nurr1 ligand-binding domain (LBD; IC50 = 48.22 nM) and increases transcriptional activity of Nurr1-LBD and full-length Nurr1 in reporter assays using SK-N-BE(2)C human neuroblastoma cells (EC50s = 6.53 and 50-70 µM, respectively). 4A7C-301-Nurr1 agonist (5 mg/kg per day) decreases dopaminergic cell death in the striatum and substantia nigra pars compacta, as well as reduces motor and olfactory deficits, without inducing dyskinesia-like behaviors in mouse models of Parkinson’s disease induced by the neurotoxin MPTP or by overexpression of α-synuclein.WARNING This product is not for human or veterinary use. | | References | [1] WOORI KIM. An optimized Nurr1 agonist provides disease-modifying effects in Parkinson’s disease models.[J]. Nature Communications, 2023, 14 1: 4283. DOI: 10.1038/s41467-023-39970-9 |
| | 4A7C-301-Nurr1 Agonist Preparation Products And Raw materials |
|